Research

Hormonal

Adjunct treatment with once-weekly semaglutide (up to 1.0 mg) produces sustained, clinically significant weight loss (mean 14.7% total weight loss) in post-bariatric patients with weight regain or insufficient weight loss over 12 months, regardless of sex or initial surgery type.

If you have regained weight or lost insufficient weight after bariatric surgery, semaglutide (a GLP-1 medication) can help you lose more weight, even if you don't have diabetes. In this study, patients lost an average of 14.7% of their body weight over a year using a dose lower than the maximum approved for obesity. This offers a medical option when lifestyle changes alone are not enough, potentially avoiding the need for revision surgery.

ModerateSupportsMEDIUM confidence
Total weight loss during semaglutide treatment added up to 14.7% ± 8.9% (mean ± SD, p < .001) after 12 months... Adjunct treatment with semaglutide resulted in sustained weight loss regardless of sex, WR or IWL and type of surgery.
Anne Lautenbach et al. · Clinical Obesity · 2023

Why this rating

Retrospective observational study with a small sample size (n=29) and no control group.

Source

Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post‐bariatric treatment failure

Anne Lautenbach et al. · Clinical Obesity · 2023

DOI 10.1111/cob.12593

cohort · n=29Cited 31×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →